

Self-administered Topical 5% Imiquimod Cream for Ext

Archives of Dermatology

134, 25

DOI: [10.1001/archderm.134.1.25](https://doi.org/10.1001/archderm.134.1.25)

Citation Report

#	ARTICLE	IF	CITATIONS
1	Imiquimod (Aldara? cream). , 1998, 6, 49-51.		10
2	Molekulare Diagnostik und Therapie der HPV-assoziierten genitalen Erkrankungen. Der Gynakologe, 1998, 31, 1057.	1.0	0
3	New antiviral agents for dermatologic disease. Seminars in Cutaneous Medicine and Surgery, 1998, 17, 243-255.	1.6	3
4	Imiquimod 5% cream (Aldaraâ,ç). Expert Opinion on Investigational Drugs, 1998, 7, 437-449.	1.9	102
5	External Genital Warts: Report of the American Medical Association Consensus Conference. Clinical Infectious Diseases, 1998, 27, 796-806.	2.9	113
6	Immune response modifiers: imiquimod. Journal of Obstetrics and Gynaecology, 1998, 18, 76-78.	0.4	9
7	A Randomized, Controlled, Molecular Study of Condylomata Acuminata Clearance during Treatment with Imiquimod. Journal of Infectious Diseases, 1998, 178, 551-555.	1.9	253
8	New Treatments for Genital Warts Less Than Ideal. JAMA - Journal of the American Medical Association, 1998, 279, 2003.	3.8	9
9	Imiquimod (AldaraTMCream). Infectious Diseases in Obstetrics and Gynecology, 1998, 6, 49-51.	0.4	8
10	Genital Warts and Their Treatment. Clinical Infectious Diseases, 1999, 28, S37-S56.	2.9	92
11	Review Article Imiquimod applied topically: a novel immune response modifier and new class of drug. International Journal of Immunopharmacology, 1999, 21, 1-14.	1.1	361
12	Modulation of TH1 and TH2 Cytokine Production with the Immune Response Modifiers, R-848 and Imiquimod. Cellular Immunology, 1999, 191, 10-19.	1.4	249
13	Dendritic Cell Maturation and Subsequent Enhanced T-Cell Stimulation Induced with the Novel Synthetic Immune Response Modifier R-848. Cellular Immunology, 1999, 197, 62-72.	1.4	108
14	Enhancement of the innate and cellular immune response in patients with genital warts treated with topical imiquimod cream 5%. Antiviral Research, 1999, 43, 55-63.	1.9	119
15	CLINICAL, HISTOPATHOLOGIC, AND MOLECULAR ASPECTS OF CUTANEOUS HUMAN PAPILLOMAVIRUS INFECTIONS. Dermatologic Clinics, 1999, 17, 521-536.	1.0	36
16	A Guide to Immunotherapy of Genital Warts. BioDrugs, 1999, 11, 319-332.	2.2	21
17	Topical imiquimod. Drugs and Therapy Perspectives, 1999, 14, 1-5.	0.3	0
18	Prophylaxis for postoperative infections often inappropriate despite clear recommendations. Drugs and Therapy Perspectives, 1999, 14, 5-7.	0.3	0

#	ARTICLE	IF	CITATIONS
19	Viral disease update. <i>Current Problems in Dermatology</i> , 1999, 11, 37-70.	0.1	10
20	Therapeutic response of basal cell carcinoma to the immune response modifier imiquimod 5% cream. <i>Journal of the American Academy of Dermatology</i> , 1999, 41, 1002-1007.	0.6	370
21	An overview of sexually transmitted diseases. Part II. <i>Journal of the American Academy of Dermatology</i> , 1999, 41, 661-680.	0.6	83
22	Modeling the impact of treatment options in genital warts: Patient-applied versus physician-administered therapies. <i>Clinical Therapeutics</i> , 1999, 21, 2143-2155.	1.1	19
23	HPV IN THE MALE PATIENT. <i>Urologic Clinics of North America</i> , 1999, 26, 797-807.	0.8	11
24	Topical Imiquimod. <i>Drugs</i> , 1999, 58, 375-390.	4.9	84
25	Do we need antivirals for genital herpes simplex virus and human papillomavirus infection?. <i>International Journal of Antimicrobial Agents</i> , 1999, 12, 1-3.	1.1	6
26	External Anogenital Warts: Old and New Therapies. <i>Journal of Obstetrics and Gynaecology Canada</i> , 1999, 21, 1305-1313.	0.1	1
27	A randomized, controlled, safety study using imiquimod for the topical treatment of anogenital warts in HIV-infected patients. <i>Aids</i> , 1999, 13, 2397-2404.	1.0	84
28	Advances in antiviral therapy. <i>Current Opinion in Pediatrics</i> , 1999, 11, 14-20.	1.0	8
29	Recent advances: Dermatology. <i>BMJ: British Medical Journal</i> , 2000, 320, 850-853.	2.4	2
30	Effect of imiquimod on cytokine induction in first trimester trophoblasts. <i>Infectious Diseases in Obstetrics and Gynecology</i> , 2000, 8, 105-111.	0.4	3
31	Immunotherapy of gynaecological high-risk human papilloma virus infection with human leukocyte ultrafiltrate. <i>Infectious Diseases in Obstetrics and Gynecology</i> , 2000, 8, 120-123.	0.4	2
32	Imiquimod, a Topical Immune Response Modifier, Induces Migration of Langerhans Cells ¹¹ The authors have declared a conflict of interest.. <i>Journal of Investigative Dermatology</i> , 2000, 114, 135-141.	0.3	257
33	Treatment of warts. <i>Dermatologic Therapy</i> , 2000, 13, 290-304.	0.8	9
34	A caution about surgical treatment for facial blushing. <i>British Journal of Dermatology</i> , 2000, 142, 194-195.	1.4	12
35	Staphylococcal toxins and the scalded skin syndrome. <i>British Journal of Dermatology</i> , 2000, 142, 195-196.	1.4	7
36	Lip papillomatosis in immunodeficiency: therapy with imiquimod. <i>British Journal of Dermatology</i> , 2000, 142, 196-197.	1.4	26

#	ARTICLE	IF	CITATIONS
37	Crusted scabies in a girl with epidermolysis bullosa simplex. <i>British Journal of Dermatology</i> , 2000, 142, 197-198.	1.4	19
38	Isotretinoin associated with craving for cigarettes. <i>British Journal of Dermatology</i> , 2000, 142, 198-199.	1.4	6
39	Self-administered topical 5% imiquimod for the treatment of common warts and molluscum contagiosum. <i>British Journal of Dermatology</i> , 2000, 143, 1026-1031.	1.4	253
40	Treatment of warts with immune response modifiers. <i>British Journal of Dermatology</i> , 2000, 143, 921-922.	1.4	13
41	Treatment of External Genital Warts. <i>Journal of Lower Genital Tract Disease</i> , 2000, 4, 128-134.	0.9	2
42	In vivo anti-papillomavirus activity of nucleoside analogues including cidofovir on CRPV-induced rabbit papillomas. <i>Antiviral Research</i> , 2000, 48, 131-142.	1.9	42
43	The 1998 CDC sexually transmitted diseases treatment guidelines. <i>Current Infectious Disease Reports</i> , 2000, 2, 44-50.	1.3	13
44	Potentiating Effect of Imiquimod in the Treatment of Verrucae Vulgares in Immunocompromised Patients. <i>Acta Dermato-Venereologica</i> , 2000, 80, 306-307.	0.6	26
45	Molecular Mechanisms of B Lymphocyte Activation by the Immune Response Modifier R-848. <i>Journal of Immunology</i> , 2000, 165, 5552-5557.	0.4	73
46	An audit of patients who have received Imiquimod cream 5% for the treatment of anogenital warts. <i>International Journal of STD and AIDS</i> , 2000, 11, 268-270.	0.5	16
47	The Management and Prevention of Premalignant Penile Lesions. <i>Scandinavian Journal of Urology and Nephrology</i> , 2000, 34, 220-229.	1.4	20
48	Recent Therapeutic Advances in Dermatology. <i>JAMA - Journal of the American Medical Association</i> , 2000, 283, 175.	3.8	15
49	Correlation between Pretreatment Levels of Interferon Response Genes and Clinical Responses to an Immune Response Modifier (Imiquimod) in Genital Warts. <i>Antimicrobial Agents and Chemotherapy</i> , 2000, 44, 1869-1873.	1.4	37
50	European course on HPV associated pathology: guidelines for primary care physicians for the diagnosis and management of anogenital warts. <i>Sexually Transmitted Infections</i> , 2000, 76, 162-168.	0.8	180
51	Immunopathogenesis of haemorrhagic enteritis virus (HEV) in turkeys. <i>Developmental and Comparative Immunology</i> , 2000, 24, 237-246.	1.0	23
52	HPV6b virus like particles are potent immunogens without adjuvant in man. <i>Vaccine</i> , 2000, 18, 1051-1058.	1.7	145
53	Imiquimod in clinical practice. <i>Journal of the American Academy of Dermatology</i> , 2000, 43, S12-S17.	0.6	52
54	Imiquimod: An immune response modifier. <i>Journal of the American Academy of Dermatology</i> , 2000, 43, S1-S5.	0.6	67

#	ARTICLE	IF	CITATIONS
55	Topical imiquimod treatment of a cutaneous melanomametastasis. <i>Journal of the American Academy of Dermatology</i> , 2000, 43, 555-556.	0.6	142
56	Cutaneous viral infections in HIV-infected individuals. <i>Clinics in Dermatology</i> , 2000, 18, 423-432.	0.8	6
57	Immune-response modifiers: a new paradigm in the treatment of human papillomavirus. <i>Current Therapeutic Research</i> , 2000, 61, 584-596.	0.5	14
58	The Imidazoquinolines, Imiquimod and R-848, Induce Functional, but Not Phenotypic, Maturation of Human Epidermal Langerhans' Cells. <i>Clinical Immunology</i> , 2000, 94, 13-23.	1.4	144
59	Recent advances in diagnosis and therapy of human papillomaviruses. <i>Expert Opinion on Investigational Drugs</i> , 2000, 9, 1753-1765.	1.9	5
60	Successful treatment of actinic keratosis with imiquimod cream 5%: a report of six cases. <i>British Journal of Dermatology</i> , 2001, 144, 1050-1053.	1.4	141
61	Phase II Double-blind, Placebo-controlled Study of the Safety and Efficacy of Cidofovir Topical Gel for the Treatment of Patients with Human Papillomavirus Infection. <i>Clinical Infectious Diseases</i> , 2001, 33, 597-602.	2.9	125
62	Imiquimod 5% cream in the treatment of Bowen's disease. <i>Journal of the American Academy of Dermatology</i> , 2001, 44, 462-470.	0.6	309
63	Imiquimod-elicited emesis is mediated by the area postrema, but not by direct neuronal activation. <i>Brain Research Bulletin</i> , 2001, 55, 445-451.	1.4	20
64	Topical immunomodulators" progress towards treating inflammation, infection, and cancer. <i>Lancet Infectious Diseases</i> , The, 2001, 1, 189-198.	4.6	139
66	PRIMARY TREATMENT OF CONDYLOMATA ACUMINATA WITH VIABLE BACILLUS CALMETTE-GUERIN. <i>Journal of Urology</i> , 2001, 165, 834-836.	0.2	26
67	Successful Treatment of Drug-resistant Cutaneous Leishmaniasis in Humans by Use of Imiquimod, an Immunomodulator. <i>Clinical Infectious Diseases</i> , 2001, 33, 1847-1851.	2.9	158
68	Effect of Adjuvant Imiquimod 5% Cream on Sustained Clearance of Anogenital Warts Following Laser Treatment. <i>Infectious Diseases in Obstetrics and Gynecology</i> , 2001, 10, 79-88.	0.4	30
69	Female Genital Warts: Global Trends and Treatments. <i>Infectious Diseases in Obstetrics and Gynecology</i> , 2001, 9, 149-154.	0.4	39
70	Human Papillomavirus Infections: Epidemiology, Pathogenesis, and Therapy. <i>Journal of Cutaneous Medicine and Surgery</i> , 2001, 5, 43-60.	0.6	67
71	Recent advances: Sexually transmitted infections. <i>BMJ: British Medical Journal</i> , 2001, 322, 1160-1164.	2.4	24
72	Safety and efficacy of imiquimod 5% cream in the treatment of penile genital warts in uncircumcised men when applied three times weekly or once per day. <i>International Journal of STD and AIDS</i> , 2001, 12, 22-28.	0.5	74
73	Chapter 18 Topical sensitization" non-oncologic indications" HPV-infections. <i>Comprehensive Series in Photosciences</i> , 2001, , 283-300.	0.3	0

#	ARTICLE	IF	CITATIONS
75	Imiquimod for the treatment of genital warts: a quantitative systematic review. BMC Infectious Diseases, 2001, 1, 3.	1.3	86
76	Assessment of acitretin-treated female patients of childbearing age and subsequent risk of teratogenicity. British Journal of Dermatology, 2001, 145, 1028-1029.	1.4	10
77	Multicentric reticulohistiocytosis associated with idiopathic myelofibrosis.. British Journal of Dermatology, 2001, 145, 1033-1034.	1.4	10
78	Pubic trichotillomania in an adult man.. British Journal of Dermatology, 2001, 145, 1034-1035.	1.4	6
79	The effect of treatment on serum levels of soluble intercellular adhesion molecules and tumour necrosis factor-receptor 1 in psoriasis.. British Journal of Dermatology, 2001, 145, 1027-1028.	1.4	7
80	Successful topical immunotherapy of bowenoid papulosis with imiquimod.. British Journal of Dermatology, 2001, 145, 1022-1023.	1.4	68
81	Acute generalized exanthematous pustulosis induced by icodextrin.. British Journal of Dermatology, 2001, 145, 1026-1027.	1.4	11
82	Why ultraviolet protection with clothing makes sense.. British Journal of Dermatology, 2001, 145, 1030-1030.	1.4	3
83	The eclipse naevus: tan centre with stellate brown rim.. British Journal of Dermatology, 2001, 145, 1023-1026.	1.4	24
84	Decreased expression of Fas (APO-1/CD95) on lesional CD4+ T lymphocytes in cutaneous T cell lymphomas: correlations with blood data.. British Journal of Dermatology, 2001, 145, 1031-1032.	1.4	4
85	Melanoma tumour markers S100B and MIA: evaluation of stability in serum and blood upon storage and processing.. British Journal of Dermatology, 2001, 145, 1030-1031.	1.4	14
86	Treatment of Anogenital Warts in Children with Topical 0.05% Podofilox Gel and 5% Imiquimod Cream. Pediatric Dermatology, 2001, 18, 448-450.	0.5	67
87	Human papillomavirus: clinical significance and malignant potential. International Journal of Dermatology, 2001, 40, 373-379.	0.5	46
88	Dermal dendritic cells in anogenital warty lesions unresponsive to an immune-response modifier. Journal of Cutaneous Pathology, 2001, 28, 131-134.	0.7	32
89	Human papillomavirus and vulval intra-epithelial neoplasia. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2001, 15, 769-782.	1.4	10
90	The treatment of human papillomavirus lesions of the lower genital tract. Best Practice and Research in Clinical Obstetrics and Gynaecology, 2001, 15, 801-816.	1.4	13
91	Imiquimod and resiquimod as novel immunomodulators. Journal of Antimicrobial Chemotherapy, 2001, 48, 751-755.	1.3	158
92	Identification of Genes Induced by a Macrophage Activator, S-28463, Using Gene Expression Array Analysis. Antimicrobial Agents and Chemotherapy, 2001, 45, 1137-1142.	1.4	35

#	ARTICLE	IF	CITATIONS
93	Combination Treatment with Intralesional Cidofovir and Viral-DNA Vaccination Cures Large Cottontail Rabbit Papillomavirus-Induced Papillomas and Reduces Recurrences. <i>Antimicrobial Agents and Chemotherapy</i> , 2001, 45, 1201-1209.	1.4	32
94	Clearance of Infection with <i>Mycobacterium bovis</i> BCG in Mice Is Enhanced by Treatment with S28463 (R-848), and Its Efficiency Depends on Expression of Wild-Type Nramp1 (Resistance Allele). <i>Antimicrobial Agents and Chemotherapy</i> , 2001, 45, 3059-3064.	1.4	17
95	Treatment of External Genital Warts in Men Using 5% Imiquimod Cream Applied Three Times a Week, Once Daily, Twice Daily, or Three Times a Day. <i>Sexually Transmitted Diseases</i> , 2001, 28, 226-231.	0.8	60
96	Emerging therapies for human papillomavirus infection. <i>Expert Opinion on Emerging Drugs</i> , 2001, 6, 199-207.	1.0	5
97	Topical imiquimod. <i>Journal of Dermatological Treatment</i> , 2001, 12, 37-40.	1.1	4
98	New patient-applied therapy for anogenital warts is rated favourably by patients. <i>International Journal of STD and AIDS</i> , 2001, 12, 565-570.	0.5	38
99	Unusually Large Cutaneous Metastases of Renal Cell Carcinoma. <i>Acta Dermato-Venereologica</i> , 2001, 81, 77-78.	0.6	16
100	Continuing medical ignorance: modern myths in the management of genital warts. <i>International Journal of STD and AIDS</i> , 2001, 12, 71-74.	0.5	12
102	European guideline for the management of anogenital warts. <i>International Journal of STD and AIDS</i> , 2001, 12, 40-47.	0.5	59
103	Imiquimod 5% Cream is a Safe and Effective Self-Applied Treatment for Anogenital Warts – Results of an Open-Label, Multicentre Phase IIIB Trial. <i>International Journal of STD and AIDS</i> , 2001, 12, 722-729.	0.5	98
104	External Genital Warts: Diagnosis, Treatment, and Prevention. <i>Clinical Infectious Diseases</i> , 2002, 35, S210-S224.	2.9	308
105	Topical imiquimod cream 5% for resistant perianal warts in a renal transplant patient. <i>International Journal of STD and AIDS</i> , 2002, 13, 501-503.	0.5	13
106	Treatment of genital warts – what's the evidence?. <i>International Journal of STD and AIDS</i> , 2002, 13, 216-222.	0.5	28
107	A Randomized, Double-blind, Vehicle-Controlled Study to Assess 5% Imiquimod Cream for the Treatment of Multiple Actinic Keratoses. <i>Archives of Dermatology</i> , 2002, 138, 1498.	1.7	202
108	The importance of patient and healthcare provider perceptions in the evaluation of imiquimod and other prior treatments for anogenital warts. <i>International Journal of STD and AIDS</i> , 2002, 13, 29-35.	0.5	5
109	Imiquimod 5-Percent Cream Does Not Alter the Natural History of Recurrent Herpes Genitalis: a Phase II, Randomized, Double-Blind, Placebo-Controlled Study. <i>Antimicrobial Agents and Chemotherapy</i> , 2002, 46, 3243-3248.	1.4	53
110	To cut a long story short - the use of imiquimod in resistant warts. <i>International Journal of STD and AIDS</i> , 2002, 13, 275-276.	0.5	0
111	Imiquimod: A Review. <i>Journal of Cutaneous Medicine and Surgery</i> , 2002, 6, 554-560.	0.6	29

#	ARTICLE	IF	CITATIONS
112	Therapeutic Response of a Brother and Sister with Xeroderma Pigmentosum to Imiquimod 5% Cream. <i>Dermatologic Surgery</i> , 2002, 28, 518-523.	0.4	0
113	Topical 5% Imiquimod Long-Term Treatment of Cutaneous Warts Resistant to Standard Therapy Modalities. <i>Dermatology</i> , 2002, 205, 139-145.	0.9	44
114	Imiquimod 5% Cream in the Treatment of Human Papillomavirus-16-Positive Erythroplasia of Queyrat. <i>Dermatology</i> , 2002, 205, 67-69.	0.9	28
115	CO ₂ Laser Surgery for Extensive, Cauliflower-Like Anogenital Condylomata acuminata: Retrospective Long-Term Study on 19 HIV-Positive and 45 HIV-Negative Men. <i>Dermatology</i> , 2002, 205, 255-259.	0.9	28
116	Increased frequency of dosing of imiquimod 5% cream in the treatment of external genital warts in women. <i>International Journal of Gynecology and Obstetrics</i> , 2002, 76, 191-193.	1.0	16
117	Imiquimod 5% cream in the treatment of anogenital warts in female patients. <i>International Journal of Gynecology and Obstetrics</i> , 2002, 77, 231-238.	1.0	25
118	Preinvasive diseases of the cervix, vulva, and vagina. <i>Seminars in Oncology Nursing</i> , 2002, 18, 184-192.	0.7	2
119	Antiviral agents: Nonantiviral drugs. <i>Journal of the American Academy of Dermatology</i> , 2002, 47, 581-599.	0.6	35
120	Clinical effect of imiquimod 5% cream in the treatment of actinic keratosis. <i>Journal of the American Academy of Dermatology</i> , 2002, 47, 553-556.	0.6	71
121	Treatment of anogenital warts with imiquimod 5% cream followed by surgical excision of residual lesions. <i>Journal of the American Academy of Dermatology</i> , 2002, 47, S212-S216.	0.6	26
122	Treatment of squamous cell carcinoma in situ of the penis with 5% imiquimod cream: A case report. <i>Journal of the American Academy of Dermatology</i> , 2002, 47, S225-S228.	0.6	60
123	Imiquimod cream in the treatment of actinic keratoses. <i>Journal of the American Academy of Dermatology</i> , 2002, 47, S236-S239.	0.6	15
124	Anecdotal reports of 3 cases illustrating a spectrum of resistant common warts treated with cryotherapy followed by topical imiquimod and salicylic acid. <i>Journal of the American Academy of Dermatology</i> , 2002, 47, S217-S220.	0.6	18
125	An open case series of patients with basal cell carcinoma treated with topical 5% imiquimod cream. <i>Journal of the American Academy of Dermatology</i> , 2002, 47, S240-S248.	0.6	27
126	Imiquimod: A cytokine inducer. <i>Journal of the American Academy of Dermatology</i> , 2002, 47, S205-S208.	0.6	63
127	Immunomodulation as a treatment strategy for genital herpes: review of the evidence. <i>International Immunopharmacology</i> , 2002, 2, 443-451.	1.7	44
128	Human papillomavirus: a review. <i>Dermatologic Clinics</i> , 2002, 20, 315-331.	1.0	63
129	Infecciones vÃ¡ricas de la piel. ClasificaciÃ³n. Formas clÃ¡nicas. Criterios diagnÃ³sticos. Actitudes terapÃ©uticas. <i>Medicine</i> , 2002, 8, 4744-4752.	0.0	0

#	ARTICLE	IF	CITATIONS
130	Imiquimod. Un medicamento del siglo XXI. <i>Piel</i> , 2002, 17, 285-291.	0.0	2
131	Anal condyloma and HIV-associated anal disease. <i>Surgical Clinics of North America</i> , 2002, 82, 1199-1211.	0.5	15
132	Local treatment of HPV-induced skin lesions by Cidofovir. <i>Journal of Medical Virology</i> , 2002, 67, 241-245.	2.5	36
134	Imiquimod: A Review. <i>Journal of Cutaneous Medicine and Surgery</i> , 2002, 6, 554-560.	0.6	53
135	Therapeutic Response of a Brother and Sister with Xeroderma Pigmentosum to Imiquimod 5% Cream. <i>Dermatologic Surgery</i> , 2002, 28, 518-523.	0.4	45
136	What's New in the Treatment of Viral Warts in Children. <i>Pediatric Dermatology</i> , 2002, 19, 191-199.	0.5	40
137	Efficacy of Imiquimod 5% Cream in the Treatment of Recalcitrant Warts in Children. <i>Pediatric Dermatology</i> , 2002, 19, 263-266.	0.5	68
141	Imiquimod: a potential role in dermatology?. <i>British Journal of Dermatology</i> , 2002, 147, 1-6.	1.4	46
142	Application of imiquimod by suppositories (anal tampons) efficiently prevents recurrences after ablation of anal canal condyloma. <i>British Journal of Dermatology</i> , 2002, 147, 757-759.	1.4	76
143	A case of melanonychia caused by <i>Fusarium solani</i> . <i>British Journal of Dermatology</i> , 2002, 147, 607-608.	1.4	5
144	Use of basiliximab as a cyclosporin-sparing agent in palmoplantar pustular psoriasis with myalgia as an adverse effect. <i>British Journal of Dermatology</i> , 2002, 147, 606-607.	1.4	15
145	Genetic syndrome with ichthyosis: congenital ichthyosis, follicular atrophoderma, hypotrichosis, and woolly hair; second report. <i>British Journal of Dermatology</i> , 2002, 147, 604-606.	1.4	22
146	Myeloid markers should be undertaken in cases of CD56 positivity to exclude granulocytic sarcoma. <i>British Journal of Dermatology</i> , 2002, 147, 609-610.	1.4	7
147	Chronic recurrent multifocal osteomyelitis: a rare association with pyoderma gangrenosum in adults. <i>British Journal of Dermatology</i> , 2002, 147, 611-612.	1.4	18
148	Danger signals and skin sensitization. <i>British Journal of Dermatology</i> , 2002, 147, 613-613.	1.4	25
149	Injury to the skin induces p53- and Fas-dependent bystander keratinocyte apoptosis in vivo. <i>British Journal of Dermatology</i> , 2002, 147, 614-616.	1.4	4
150	Scleroderma-like drug reaction to paclitaxel (TaxolR). <i>British Journal of Dermatology</i> , 2002, 147, 619-620.	1.4	34
151	Cutaneous lesions of Churg-Strauss syndrome associated with montelukast therapy. <i>British Journal of Dermatology</i> , 2002, 147, 618-618.	1.4	15

#	ARTICLE	IF	CITATIONS
152	Sartans, angiotensin II receptor antagonists, can induce psoriasis. <i>British Journal of Dermatology</i> , 2002, 147, 617-618.	1.4	44
153	Localized toxic pustuloderma associated with nimesulide therapy confirmed by patch testing. <i>British Journal of Dermatology</i> , 2002, 147, 624-624.	1.4	13
154	Successful treatment of erosive vulvovaginal lichen planus with topical tacrolimus. <i>British Journal of Dermatology</i> , 2002, 147, 625-626.	1.4	62
155	Topical imiquimod eradicates skin metastases of malignant melanoma but fails to prevent rapid lymphogenous metastatic spread. <i>British Journal of Dermatology</i> , 2002, 147, 621-623.	1.4	61
156	Isolated thrombocytopenia associated with oral terbinafine. <i>British Journal of Dermatology</i> , 2002, 147, 627-628.	1.4	10
157	Basal cell carcinoma arising in professional radiodermatitis of the nail. <i>British Journal of Dermatology</i> , 2002, 147, 628-628.	1.4	14
158	Imiquimod and the imidazoquinolones: mechanism of action and therapeutic potential. <i>Clinical and Experimental Dermatology</i> , 2002, 27, 571-577.	0.6	330
159	Imiquimod 5% cream is an acceptable treatment option for external anogenital warts in uncircumcised males. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2002, 16, 58-62.	1.3	11
160	Imiquimod; an international update on therapeutic uses in dermatology. <i>International Journal of Dermatology</i> , 2002, 41, 810-816.	0.5	46
161	Topische Immunmodulation in der Dermatologie. Topical immunmodulation in dermatology. <i>Zeitschrift für Hautkrankheiten</i> , 2002, 77, 116-130.	0.0	0
162	Erfolgreiche Therapie der fokalen epithelialen Hyperplasie (M. Heck) mit 5 % Imiquimod. Therapy of the focal epithelial hyperplasia (Heck's disease) with 5 % of imiquimod. <i>Zeitschrift für Hautkrankheiten</i> , 2002, 77, 191-193.	0.0	3
163	Imiquimod und die Imidazochinolone: Wirkungsmechanismus und therapeutisches Potenzial. Imiquimod and the imidazoquinolones: mechanism of action and therapeutic potential. <i>Zeitschrift für Hautkrankheiten</i> , 2002, 77, 650-655.	0.0	0
164	Imiquimod 5% cream: a topical immune response modifier. <i>International Journal of Dermatology</i> , 2002, 41, 1-2.	0.5	13
165	Imiquimod stimulates innate and cell mediated immunity which controls virus infections and tumors. <i>International Journal of Dermatology</i> , 2002, 41, 3-6.	0.5	27
166	Imiquimod: a new immune response modifier for the treatment of external genital warts and other diseases in dermatology. <i>International Journal of Dermatology</i> , 2002, 41, 7-11.	0.5	26
167	Imiquimod in the treatment of actinic keratoses and other intraepithelial neoplasms. <i>International Journal of Dermatology</i> , 2002, 41, 12-15.	0.5	16
168	The Effects of 5% Imiquimod Cream on High-Grade Vulval Intraepithelial Neoplasia. <i>Gynecologic Oncology</i> , 2002, 85, 67-70.	0.6	69
169	Photodynamic Therapy for Human Papilloma Virus-Related Diseases in Dermatology. Medical Laser Application: <i>International Journal for Laser Treatment and Research</i> , 2003, 18, 107-116.	0.4	6

#	ARTICLE	IF	CITATIONS
170	Sexually transmitted diseases in men who have sex with men: A clinical review. <i>Current Infectious Disease Reports</i> , 2003, 5, 135-144.	1.3	21
172	Bowenoid papulosis of the vulva—immunotherapeutical approach with topical imiquimod. <i>Archives of Gynecology and Obstetrics</i> , 2003, 268, 333-336.	0.8	24
173	Malignant conversion of florid oral and labial papillomatosis during topical immunotherapy with imiquimod. <i>Medical Microbiology and Immunology</i> , 2003, 192, 161-164.	2.6	12
174	Genital and perianal warts: new treatment opportunities for human papillomavirus infection. <i>American Journal of Obstetrics and Gynecology</i> , 2003, 189, S3-S11.	0.7	58
175	The Toll-like receptor 7 (TLR7)-specific stimulus loxoribine uncovers a strong relationship within the TLR7, 8 and 9 subfamily. <i>European Journal of Immunology</i> , 2003, 33, 2987-2997.	1.6	487
176	Topical immunomodulators for the treatment of external genital warts, cutaneous warts and molluscum contagiosum. <i>British Journal of Dermatology</i> , 2003, 149, 15-19.	1.4	59
177	Viral warts in organ transplant recipients: new aspects in therapy. <i>British Journal of Dermatology</i> , 2003, 149, 20-24.	1.4	60
178	Induction of apoptosis by Toll-like receptor-7 agonist in tissue cultures. <i>British Journal of Dermatology</i> , 2003, 149, 9-13.	1.4	74
179	Immunotherapy for Recalcitrant Warts in Children Using Intralesional Mumps or Candida Antigens. <i>Pediatric Dermatology</i> , 2003, 20, 268-271.	0.5	150
180	Successful treatment of multiple filiform facial warts with imiquimod 5% cream in a patient infected by human immunodeficiency virus. <i>Clinical and Experimental Dermatology</i> , 2003, 28, 260-261.	0.6	13
181	A review of imiquimod 5% cream for the treatment of various dermatological conditions. <i>Clinical and Experimental Dermatology</i> , 2003, 28, 1-3.	0.6	10
182	The treatment of basal skin carcinomas in two sisters with xeroderma pigmentosum. <i>Clinical and Experimental Dermatology</i> , 2003, 28, 30-32.	0.6	25
183	The treatment of basal cell carcinomas in a patient with xeroderma pigmentosum with a combination of imiquimod 5% cream and oral acitretin. <i>Clinical and Experimental Dermatology</i> , 2003, 28, 33-35.	0.6	31
184	Successful treatment of extramammary Paget's disease of the scrotum with imiquimod 5% cream. <i>Clinical and Experimental Dermatology</i> , 2003, 28, 36-38.	0.6	46
185	Successful treatment of butcher's warts with imiquimod 5% cream. <i>Clinical and Experimental Dermatology</i> , 2003, 28, 42-44.	0.6	9
186	Plantar warts treated with an immune response modifier: a report of two cases. <i>Clinical and Experimental Dermatology</i> , 2003, 28, 45-47.	0.6	11
187	Topical treatment of common warts in an HIV-positive patient with imiquimod 5% cream. <i>Clinical and Experimental Dermatology</i> , 2003, 28, 48-50.	0.6	8
188	Extensive condyloma acuminata treated with imiquimod 5% cream: a case report. <i>Clinical and Experimental Dermatology</i> , 2003, 28, 51-54.	0.6	4

#	ARTICLE	IF	CITATIONS
189	Topical treatment of intraepithelial penile carcinoma with imiquimod. <i>Clinical and Experimental Dermatology</i> , 2003, 28, 4-6.	0.6	48
190	Treatment of Bowen's disease using a cycle regimen of imiquimod 5% cream. <i>Clinical and Experimental Dermatology</i> , 2003, 28, 10-12.	0.6	27
191	Treatment of facial superficial basal cell carcinomas with imiquimod 5% cream. <i>Clinical and Experimental Dermatology</i> , 2003, 28, 16-18.	0.6	5
192	The use of imiquimod 5% cream for the treatment of basal cell carcinoma as observed in Gorlin's syndrome. <i>Clinical and Experimental Dermatology</i> , 2003, 28, 19-23.	0.6	44
194	Sexually transmitted infections in men. <i>Primary Care - Clinics in Office Practice</i> , 2003, 30, 173-191.	0.7	9
195	Imiquimod. <i>Dermatologic Clinics</i> , 2003, 21, 291-300.	1.0	69
196	Local treatment of viral disease using photodynamic therapy. <i>International Journal of Antimicrobial Agents</i> , 2003, 21, 510-520.	1.1	95
197	Lowenstein tumour in pregnancy. <i>European Journal of Obstetrics, Gynecology and Reproductive Biology</i> , 2003, 111, 88-90.	0.5	7
198	The Immune Response Modifier and Toll-Like Receptor 7 Agonist S-27609 Selectively Induces IL-12 and TNF- α Production in CD11c+CD11b+CD8 α^+ Dendritic Cells. <i>Journal of Immunology</i> , 2003, 171, 1156-1163.	0.4	94
199	Randomized, Single-Blind, Placebo-Controlled Study of Topical Application of the Immune Response Modulator Resiquimod in Healthy Adults. <i>Antimicrobial Agents and Chemotherapy</i> , 2003, 47, 3846-3852.	1.4	72
200	Injection of Immature Dendritic Cells into Adjuvant-Treated Skin Obviates the Need for Ex Vivo Maturation. <i>Journal of Immunology</i> , 2003, 171, 6275-6282.	0.4	160
201	Imiquimod. <i>Archives of Dermatology</i> , 2003, 139, 1347-50.	1.7	53
202	Update on Genital Lesions. <i>JAMA - Journal of the American Medical Association</i> , 2003, 290, 1001.	3.8	18
203	3. Successful Management of Viral Infections and Other Dermatoses with Imiquimod 5% Cream. <i>Acta Dermato-Venereologica</i> , 2003, 83, 12-17.	0.6	8
204	The cost-effectiveness of patient-applied treatments for anogenital warts. <i>International Journal of STD and AIDS</i> , 2003, 14, 228-234.	0.5	18
205	5. Imiquimod 5% Cream for the Treatment of Cutaneous Lesions in Immunocompromised Patients. <i>Acta Dermato-Venereologica</i> , 2003, 83, 23-27.	0.6	2
206	Imiquimod. <i>Current Opinion in Infectious Diseases</i> , 2003, 16, 85-89.	1.3	86
207	Topical Imiquimod 5% Cream as an Effective Treatment for External Genital and Perianal Warts in Different Patient Populations. <i>Sexually Transmitted Diseases</i> , 2003, 30, 124-128.	0.8	58

#	ARTICLE	IF	CITATIONS
208	Treatment of Vaginal Intraepithelial Neoplasia (Primarily Low Grade) with Imiquimod 5% Cream. <i>Journal of Lower Genital Tract Disease</i> , 2003, 7, 290-293.	0.9	46
209	Treatment of Basal Cell Carcinoma. , 0, , 477-491.		0
210	Prolonged Imiquimod Treatment and Graft-versus-Host Reaction: Histological Mimicry in the Skin Infiltration Pattern of the Monocyte-Macrophage-Dendrocyte Lineage. <i>Dermatology</i> , 2003, 206, 361-365.	0.9	16
211	Treatment of Undifferentiated Vulvar Intraepithelial Neoplasia With 5% Imiquimod Cream. <i>Archives of Dermatology</i> , 2004, 140, 1220-4.	1.7	30
212	Correspondence. <i>Journal of Dermatological Treatment</i> , 2004, 15, 118-119.	1.1	33
213	Molecular Analysis of the Effect of Topical Imiquimod Treatment of HPV 2/27/57-Induced Common Warts. <i>Skin Pharmacology and Physiology</i> , 2004, 17, 258-266.	1.1	13
214	Imiquimod as a dermatological therapy. <i>Expert Opinion on Pharmacotherapy</i> , 2004, 5, 427-438.	0.9	25
215	Therapeutic Evaluation of Intralesional 5% 5-Fluorouracil in Condyloma Acuminata. <i>Journal of Dermatology</i> , 2004, 31, 314-325.	0.6	5
216	Using Imiquimod for Genital Warts in Female Patients. <i>Journal of Women's Health</i> , 2004, 13, 265-271.	1.5	16
217	5% Imiquimod cream for external anogenital warts in HIV-infected patients under HAART therapy. <i>International Journal of STD and AIDS</i> , 2004, 15, 17-20.	0.5	40
219	Therapy of external anogenital warts and molluscum contagiosum: a literature review. <i>Dermatologic Therapy</i> , 2004, 17, 68-101.	0.8	47
220	Therapy of cutaneous human Papillomavirus infections. <i>Dermatologic Therapy</i> , 2004, 17, 441-448.	0.8	84
221	Treatment of external genital warts with 5% imiquimod cream during pregnancy: a case report. <i>BJOG: an International Journal of Obstetrics and Gynaecology</i> , 2004, 111, 1475-1475.	1.1	20
222	Topical Immunomodulation in Dermatology: Potential of Toll-like Receptor Agonists. <i>Dermatologic Surgery</i> , 2004, 30, 1101-1112.	0.4	60
223	Closing the feedback loop: an audit of the use of imiquimod for the treatment of genital warts. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2004, 18, 314-317.	1.3	7
224	Lactoferrin inhibits human papillomavirus binding and uptake in vitro. <i>Antiviral Research</i> , 2004, 64, 63-68.	1.9	52
225	Safety and efficacy of locally applied imiquimod cream 5% for the treatment of condylomata acuminata of the vulva. <i>Archives of Gynecology and Obstetrics</i> , 2004, 270, 240-243.	0.8	7
226	Role of Topical Therapies in the Management of Cutaneous Disease. <i>Journal of Cutaneous Medicine and Surgery</i> , 2004, 8, 22-31.	0.6	10

#	ARTICLE	IF	CITATIONS
233	Genital warts. <i>Clinics in Dermatology</i> , 2004, 22, 481-486.	0.8	44
234	Imiquimod 5% cream for the treatment of actinic keratosis: Results from a phase III, randomized, double-blind, vehicle-controlled, clinical trial with histology. <i>Journal of the American Academy of Dermatology</i> , 2004, 51, 547-555.	0.6	186
235	Imiquimod, a Toll-like receptor-7 agonist, induces perforin in cytotoxic T lymphocytes in vitro. <i>Molecular Immunology</i> , 2004, 40, 1307-1314.	1.0	38
236	Topical Imiquimod 5% Cream in External Anogenital Warts: A Randomized, Double-Blind, Placebo-Controlled Study. <i>Journal of Dermatology</i> , 2004, 31, 627-631.	0.6	67
237	Topical Immunomodulation in Dermatology. <i>Dermatologic Surgery</i> , 2004, 30, 1101-1112.	0.4	30
238	Human papillomavirus and cervical cytology in adolescents. <i>Adolescent Medicine Clinics</i> , 2004, 15, 301-321.	0.8	20
239	Imiquimod Treatment of Exuberant Granulation Tissue in a Nonhealing Diabetic Ulcer. <i>Archives of Dermatology</i> , 2005, 141, 1368.	1.7	7
240	Medical Management of Vulvar Intraepithelial Neoplasia. <i>Journal of Lower Genital Tract Disease</i> , 2005, 9, 206-212.	0.9	13
241	Imiquimod Treatment of Superficial and Nodular Basal Cell Carcinoma. <i>Dermatologic Surgery</i> , 2005, 31, 318-323.	0.4	37
242	Current and Potential Uses of Imiquimod. <i>Southern Medical Journal</i> , 2005, 98, 913-919.	0.3	62
243	Squamous Vulvar Intraepithelial Neoplasia. <i>Clinical Obstetrics and Gynecology</i> , 2005, 48, 845-861.	0.6	70
244	Successful treatment of malignant melanoma in situ with topical 5% imiquimod cream. <i>International Journal of Dermatology</i> , 2005, 44, 428-434.	0.5	50
245	Imiquimod cream 5% for recalcitrant cutaneous warts in immunosuppressed individuals. <i>British Journal of Dermatology</i> , 2005, 152, 122-129.	1.4	67
246	The road to new antiviral therapies. <i>Clinical and Applied Immunology Reviews</i> , 2005, 5, 65-76.	0.4	5
247	Complementary therapy and genital warts. <i>Sexually Transmitted Infections</i> , 2005, 81, 360-360.	0.8	3
248	Achievements and Challenges in Antiviral Drug Discovery. <i>Antiviral Chemistry and Chemotherapy</i> , 2005, 16, 155-168.	0.3	51
249	A prediction rule for selective screening of <i>Chlamydia trachomatis</i> infection. <i>Sexually Transmitted Infections</i> , 2005, 81, 24-30.	0.8	93
250	Randomized, Double-Blind Clinical Trial of Topical Imiquimod 5% with Parenteral Meglumine Antimoniate in the Treatment of Cutaneous Leishmaniasis in Peru. <i>Clinical Infectious Diseases</i> , 2005, 40, 1395-1403.	2.9	111

#	ARTICLE	IF	CITATIONS
251	Evaluation of Imiquimod 5% Cream to Modify the Natural History of Herpes Labialis: A Pilot Study. <i>Clinical Infectious Diseases</i> , 2005, 41, 808-814.	2.9	40
252	Intralesional Immunotherapy for Genital Warts. <i>Archives of Dermatology</i> , 2005, 141, 1606-7.	1.7	46
253	Treating Opportunistic Infections among HIV-Infected Adults and Adolescents: Recommendations from CDC, the National Institutes of Health, and the HIV Medicine Association/Infectious Diseases Society of America. <i>Clinical Infectious Diseases</i> , 2005, 40, S131-S235.	2.9	72
254	www.archdermatol.com Communicates With the International Dermatology Community. <i>Archives of Dermatology</i> , 2005, 141, 505-6.	1.7	2
255	Infliximab Combined With Methotrexate as Long-term Treatment for Erythrodermic Psoriasis. <i>Archives of Dermatology</i> , 2005, 141, 1607-10.	1.7	26
256	Safety and Efficacy of 5% Imiquimod Cream for the Treatment of Skin Dysplasia in High-Risk Renal Transplant Recipients. <i>Archives of Dermatology</i> , 2005, 141, 985-93.	1.7	99
257	Imiquimod for the treatment of skin cancer. <i>Dermatologic Clinics</i> , 2005, 23, 151-164.	1.0	36
259	Therapy for genital human papillomavirus-related disease. <i>Journal of Clinical Virology</i> , 2005, 32, 82-90.	1.6	138
260	Application of viable bacille Calmette-Guérin topically as a potential therapeutic modality in condylomata acuminata: A placebo-controlled study. <i>Urology</i> , 2005, 65, 247-250.	0.5	43
261	Synthesis and Structure-Activity-Relationships of 1H-Imidazo[4,5-c]quinolines That Induce Interferon Production. <i>Journal of Medicinal Chemistry</i> , 2005, 48, 3481-3491.	2.9	112
262	Viral Infections Affecting the Skin in Organ Transplant Recipients. <i>American Journal of Clinical Dermatology</i> , 2006, 7, 13-29.	3.3	110
263	TLR7 Ligands Induce Higher IFN- γ Production in Females. <i>Journal of Immunology</i> , 2006, 177, 2088-2096.	0.4	394
264	Topical imiquimod: effectiveness in intraepithelial melanoma of oral mucosa. <i>Lancet Oncology</i> , The, 2006, 7, 1036-1037.	5.1	23
265	Meta-Analysis of 5% Imiquimod and 0.5% Podophyllotoxin in the Treatment of Condylomata Acuminata. <i>Dermatology</i> , 2006, 213, 218-223.	0.9	72
266	Dermatoproctologia. EMC - Dermatologia, 2006, 40, 1-6.	0.1	0
267	Oral and vulvar changes in pregnancy. <i>Clinics in Dermatology</i> , 2006, 24, 122-132.	0.8	36
268	Chapter 14: HPV vaccine introduction in industrialized countries. <i>Vaccine</i> , 2006, 24, S122-S131.	1.7	37
269	Chapter 4: Burden and management of non-cancerous HPV-related conditions: HPV-6/11 disease. <i>Vaccine</i> , 2006, 24, S35-S41.	1.7	403

#	ARTICLE	IF	CITATIONS
270	Topical Therapy for Actinic Keratoses: Current and Evolving Therapies. Reviews on Recent Clinical Trials, 2006, 1, 53-60.	0.4	25
271	Recalcitrant Verrucous Lesion. Journal of the American Podiatric Medical Association, 2006, 96, 148-153.	0.2	2
273	Immune response modifiers ? mode of action. Experimental Dermatology, 2006, 15, 331-341.	1.4	100
274	Imiquimod Treatment of Superficial and Nodular Basal Cell Carcinoma: 12-Week Open-Label Trial. Dermatologic Surgery, 2006, 31, 318-323.	0.4	43
275	Treatment of flat warts with 5% imiquimod cream. Journal of the European Academy of Dermatology and Venereology, 2006, 20, 1349-1350.	1.3	8
276	Erythema multiforme presenting as cholestatic acute hepatitis caused by Epstein-Barr virus. Journal of the European Academy of Dermatology and Venereology, 2006, 20, 1350-1352.	1.3	6
277	Role of SLC11A1 (formerly NRAMP1) in regulation of signal transduction induced by Toll-like receptor 7 ligands. FEMS Immunology and Medical Microbiology, 2006, 47, 138-147.	2.7	10
278	Efficacy of imiquimod 5% cream in the treatment of equine sarcoids: a pilot study. Veterinary Dermatology, 2006, 17, 259-265.	0.4	55
279	Preliminary results of 5% imiquimod cream in the primary treatment of vulva intraepithelial neoplasia grade 2/3. American Journal of Obstetrics and Gynecology, 2006, 194, 377-380.	0.7	29
281	New antiviral agents. Indian Journal of Pediatrics, 2006, 73, 313-321.	0.3	22
282	Papillomavirus and treatment. Antiviral Research, 2006, 71, 181-191.	1.9	41
283	The use of topical 5% imiquimod during pregnancy: A case series. Reproductive Toxicology, 2006, 21, 1-2.	1.3	25
284	Nursing care and treatment of the patient with human papillomavirus. British Journal of Nursing, 2006, 15, 1063-1069.	0.3	4
285	An open-label phase II pilot study investigating the optimal duration of imiquimod 5% cream for the treatment of external genital warts in women. International Journal of STD and AIDS, 2006, 17, 448-452.	0.5	32
286	Immunotherapy of skin diseases caused by the human papillomavirus. Expert Review of Dermatology, 2006, 1, 131-135.	0.3	0
287	The sexually transmitted papillomavirus infections: clinical manifestations, current and future therapies. Expert Opinion on Therapeutic Patents, 2007, 17, 173-211.	2.4	0
288	Part II: Anorectal Disorders. , 2007, , 167-190.		0
289	Treatment of External Genital Warts and Pre-invasive Neoplasia of the Lower Tract. Journal of Obstetrics and Gynaecology Canada, 2007, 29, S37-S41.	0.3	1

#	ARTICLE	IF	CITATIONS
291	HPV-related vulvar intraepithelial neoplasia: Outcome of different management modalities. <i>International Journal of Gynecology and Obstetrics</i> , 2007, 99, 23-27.	1.0	23
292	Resiquimod and other immune response modifiers as vaccine adjuvants. <i>Expert Review of Vaccines</i> , 2007, 6, 835-847.	2.0	72
293	Vulvo-Vaginal Cancers: Risks, Evaluation, Prevention and Early Detection. <i>Obstetrics and Gynecology Clinics of North America</i> , 2007, 34, 783-802.	0.7	40
294	Topical Imiquimod. <i>Drugs</i> , 2007, 67, 2187-2210.	4.9	96
295	Experimental and theoretical study on the structure and electronic spectra of imiquimod and its synthetic intermediates. <i>Bioorganic and Medicinal Chemistry Letters</i> , 2007, 17, 4942-4946.	1.0	11
296	Anal intraepithelial neoplasia and anal cancer in dermatological practice. <i>Australasian Journal of Dermatology</i> , 2007, 48, 143-155.	0.4	11
297	Vehicle-controlled, randomized, double-blind study to assess safety and efficacy of imiquimod 5% cream applied once daily 3 days per week in one or two courses of treatment of actinic keratoses on the head. <i>British Journal of Dermatology</i> , 2007, 157, 133-141.	1.4	110
298	Imiquimod treatment of papilloma virus and DMBA/TPA-induced cutaneous skin cancer in <i>Mastomys coucha</i> : an unique animal model system useful for preclinical studies. <i>British Journal of Dermatology</i> , 2007, 157, 14-17.	1.4	3
299	Evaluation of imiquimod for the therapy of external genital and anal warts in comparison with destructive therapies. <i>British Journal of Dermatology</i> , 2007, 157, 52-55.	1.4	29
300	Topical zinc oxide vs. salicylic acid/lactic acid combination in the treatment of warts. <i>International Journal of Dermatology</i> , 2007, 46, 427-430.	0.5	41
301	A randomized, double-blind, four-arm parallel-group, placebo-controlled Phase II/III study to investigate the clinical efficacy of two galenic formulations of Polyphenon® E in the treatment of external genital warts. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2007, 21, 1404-1412.	1.3	93
302	Final results of a phase 2 study using continuous 5% Imiquimod cream application in the primary treatment of high-grade vulva intraepithelial neoplasia. <i>Gynecologic Oncology</i> , 2007, 106, 579-584.	0.6	48
303	Topical imiquimod can reverse vulvar intraepithelial neoplasia: A randomised, double-blinded study. <i>Gynecologic Oncology</i> , 2007, 107, 219-222.	0.6	96
304	Human papillomavirus type predict the clinical outcome of imiquimod therapy for women with vulvar condylomata acuminata*. <i>Acta Obstetrica Et Gynecologica Scandinavica</i> , 2007, 86, 968-972.	1.3	6
305	Earlier Eradication of Intra-Anal Warts with Argon Plasma Coagulator Combined with Imiquimod Cream Compared with Argon Plasma Coagulator Alone: A Prospective, Randomized Trial. <i>Diseases of the Colon and Rectum</i> , 2007, 50, 2173-2179.	0.7	17
306	3,3'-Diindolylmethane stimulates murine immune function in vitro and in vivo. <i>Journal of Nutritional Biochemistry</i> , 2008, 19, 336-344.	1.9	33
308	TLR7 stimulation augments T _H 1 effector-mediated rejection of skin expressing neo-self antigen in keratinocytes. <i>European Journal of Immunology</i> , 2008, 38, 73-81.	1.6	18
309	Toll-like receptors control autophagy. <i>EMBO Journal</i> , 2008, 27, 1110-1121.	3.5	673

#	ARTICLE	IF	CITATIONS
310	Pharmacokinetics and Safety of Imiquimod 5% Cream in the Treatment of Molluscum Contagiosum in Children. <i>Pediatric Dermatology</i> , 2008, 25, 88-95.	0.5	37
311	Recent advances in management of genital ulcer disease and anogenital warts. <i>Dermatologic Therapy</i> , 2008, 21, 196-204.	0.8	10
312	Topical imiquimod and intralesional interleukin-2 increase activated lymphocytes and restore the Th1/Th2 balance in patients with metastatic melanoma. <i>British Journal of Dermatology</i> , 2008, 159, 606-614.	1.4	48
314	Clinical investigations of Toll-like receptor agonists. <i>Expert Opinion on Investigational Drugs</i> , 2008, 17, 1051-1065.	1.9	71
315	An immunological perspective on skin disease. <i>Drug Discovery Today Disease Mechanisms</i> , 2008, 5, e3-e9.	0.8	0
317	Comparison of cryotherapy to imiquimod 5% in the treatment of anogenital warts. <i>International Journal of STD and AIDS</i> , 2008, 19, 441-444.	0.5	29
318	Topical imiquimod: a guide to its use in anogenital warts, actinic keratoses and basal cell carcinoma. <i>Drugs and Therapy Perspectives</i> , 2008, 24, 1-4.	0.3	0
319	Optimal Frequency of Imiquimod (Aldara) 5% Cream for the Treatment of External Genital Warts in Immunocompetent Adults: A Meta-Analysis. <i>Sexually Transmitted Diseases</i> , 2008, 35, 346-351.	0.8	29
322	Modern Management of External Genital Warts. <i>Journal of Lower Genital Tract Disease</i> , 2008, 12, 185-192.	0.9	35
323	IMIQUIMOD EN CREMA AL 5% EN EL TRATAMIENTO DE VERRUGAS ANOGENITALES ASOCIADAS A VPH: EXPERIENCIA PRELIMINAR. <i>Revista Chilena De Obstetricia Y Ginecologia</i> , 2008, 73, .	0.1	1
324	Advances in the use of topical imiquimod to treat dermatologic disorders. <i>Therapeutics and Clinical Risk Management</i> , 2008, Volume 4, 87-97.	0.9	36
325	A Review of Topical Imiquimod in the Management of Basal Cell Carcinoma, Actinic Keratoses, and Other Skin Lesions. <i>Clinical Medicine Therapeutics</i> , 2009, 1, CMT.S1969.	0.1	0
326	Sexually transmitted papillomavirus infections: epidemiology pathogenesis, clinic, morphology, important differential diagnostic aspects, current diagnostic and treatment options. <i>Anais Brasileiros De Dermatologia</i> , 2009, 84, 377-389.	0.5	24
327	Efficacy of Hypnosis in the Treatment of Human Papillomavirus (HPV) in Women: Rural and Urban Samples. <i>International Journal of Clinical and Experimental Hypnosis</i> , 2009, 58, 102-121.	1.1	8
328	A study on the use of imiquimod for the treatment of genital molluscum contagiosum and genital warts in female patients. <i>Indian Journal of Sexually Transmitted Diseases and AIDS</i> , 2009, 30, 84.	0.6	10
329	Successful treatment of profuse recalcitrant extra-genital warts in an HIV-positive patient using 5% imiquimod cream. <i>International Journal of STD and AIDS</i> , 2009, 20, 657-658.	0.5	4
330	Safety and preliminary efficacy data of a novel Casein Kinase 2 (CK2) peptide inhibitor administered intralesionally at four dose levels in patients with cervical malignancies. <i>BMC Cancer</i> , 2009, 9, 146.	1.1	64
331	Dermatologic manifestations of HPV in HIV-infected individuals. <i>Current HIV/AIDS Reports</i> , 2009, 6, 130-138.	1.1	44

#	ARTICLE	IF	CITATIONS
333	Imiquimod 5% cream for external genital or perianal warts in human immunodeficiency virus-positive patients treated with highly active antiretroviral therapy: an open-label, noncomparative study. <i>British Journal of Dermatology</i> , 2009, 161, 904-909.	1.4	33
334	Effect of dosing frequency on the safety and efficacy of imiquimod 5% cream for treatment of actinic keratosis on the forearms and hands: a phase II, randomized placebo-controlled trial. <i>British Journal of Dermatology</i> , 2009, 161, 897-903.	1.4	47
335	A Phase II, Open-Label Study of the Efficacy and Safety of Imiquimod in the Treatment of Superficial and Mixed Infantile Hemangioma. <i>Pediatric Dermatology</i> , 2009, 26, 203-212.	0.5	62
336	Comparative Study on the Efficacy, Safety, and Acceptability of Imiquimod 5% Cream versus Cryotherapy for Molluscum Contagiosum in Children. <i>Pediatric Dermatology</i> , 2010, 27, 388-394.	0.5	61
337	A pharmaceutical comparison of different commercially available imiquimod 5% cream products. <i>Journal of Dermatological Treatment</i> , 2009, 20, 160-164.	1.1	11
338	Topical treatment of anogenital human papillomavirus infection in male patients. <i>Future Virology</i> , 2009, 4, 531-541.	0.9	3
339	An overview of human papillomavirus infection for the dermatologist: disease, diagnosis, management, and prevention. <i>Dermatologic Therapy</i> , 2010, 23, 458-476.	0.8	58
340	Herpes simplex virus and human papillomavirus genital infections: new and investigational therapeutic options. <i>International Journal of Dermatology</i> , 2010, 49, 733-749.	0.5	21
341	Polyphenon E [®] : a new treatment for external anogenital warts. <i>British Journal of Dermatology</i> , 2010, 162, 176-184.	1.4	90
342	Acitretin systemic and retinoic acid 0.1% cream suppression of basal cell carcinoma. <i>Dermatology Reports</i> , 2010, 2, 4.	0.4	2
343	Reflectance Confocal Microscopy for Noninvasive Monitoring of Therapy and Detection of Subclinical Actinic Keratoses. <i>Dermatology</i> , 2010, 220, 15-24.	0.9	143
344	Topical Imiquimod for Periocular Lentigo Maligna. <i>Ophthalmology</i> , 2010, 117, 2424-2429.	2.5	33
345	Effect of imiquimod on partial-thickness burns. <i>Burns</i> , 2010, 36, 97-108.	1.1	18
346	An Intranasally Delivered Toll-Like Receptor 7 Agonist Elicits Robust Systemic and Mucosal Responses to Norwalk Virus-Like Particles. <i>Vaccine Journal</i> , 2010, 17, 1850-1858.	3.2	45
348	Imiquimod 3.75% cream (Zyclara) for the treatment of actinic keratoses. <i>Expert Opinion on Pharmacotherapy</i> , 2011, 12, 451-461.	0.9	24
350	Diagnosis and Treatment of Anal Intraepithelial Neoplasia and Condylomata. <i>Seminars in Colon and Rectal Surgery</i> , 2011, 22, 21-29.	0.2	0
351	Update on diagnosis, treatment, and prevention of genital human papillomavirus manifestations. <i>Osteopathic Family Physician</i> , 2011, 3, 106-111.	0.2	1
352	Appraisal of the burden of genital warts from a healthcare and individual patient perspective. <i>Public Health</i> , 2011, 125, 464-475.	1.4	28

#	ARTICLE	IF	CITATIONS
353	Efficacy and Safety of Imiquimod Versus Podophyllotoxin in the Treatment of Anogenital Warts. Sexually Transmitted Diseases, 2011, 38, 216-218.	0.8	55
354	Complete regression of subcutaneous and cutaneous metastatic melanoma with high-dose intralesional interleukin 2 in combination with topical imiquimod and retinoid cream. Melanoma Research, 2011, 21, 235-243.	0.6	35
356	Imiquimod 3.75% Cream Applied Daily to Treat Anogenital Warts: Combined Results from Women in Two Randomized, Placebo-Controlled Studies. Infectious Diseases in Obstetrics and Gynecology, 2011, 2011, 1-11.	0.4	43
358	Topical Antineoplastic Agents in the Treatment of Mucocutaneous Diseases. Current Problems in Dermatology, 2011, 40, 71-82.	0.8	9
359	Local and systemic adverse effects of imiquimod therapy for external anogenital warts in men: report of three cases. International Journal of STD and AIDS, 2012, 23, 909-910.	0.5	16
360	Trial watch: FDA-approved Toll-like receptor agonists for cancer therapy. Oncolmunology, 2012, 1, 894-907.	2.1	194
361	Pharmacokinetics of Daily Self-Application of Imiquimod 3.75% Cream in Adult Patients With External Anogenital Warts. Journal of Clinical Pharmacology, 2012, 52, 828-836.	1.0	6
362	Topical Imiquimod 5% cream therapy for external anogenital warts in pregnant women: Report of four cases and review of the literature. Journal of Maternal-Fetal and Neonatal Medicine, 2012, 25, 873-876.	0.7	15
363	Oral HPV Infection: Current Strategies for Prevention and Therapy. Current Pharmaceutical Design, 2012, 18, 5452-5469.	0.9	22
365	Traditional Chinese medicinal herbs for condyloma acuminatum. The Cochrane Library, 0, , .	1.5	2
366	The use of sinecatechins (polyphenon E) ointment for treatment of external genital warts. Expert Opinion on Biological Therapy, 2012, 12, 783-793.	1.4	39
367	Human papillomavirus-related genital disease in the immunocompromised host. Journal of the American Academy of Dermatology, 2012, 66, 883.e1-883.e17.	0.6	71
368	Evidence-Based Treatment and Prevention of External Genital Warts in Female Pediatric and Adolescent Patients. Journal of Pediatric and Adolescent Gynecology, 2012, 25, 150-154.	0.3	14
369	CD70-CD27 Interaction Augments CD8+ T-Cell Activation by Human Epidermal Langerhans Cells. Journal of Investigative Dermatology, 2012, 132, 1636-1644.	0.3	59
370	Topical imiquimod treatment for human papillomavirus infection in patients with and without cervical/vaginal intraepithelial neoplasia. Taiwanese Journal of Obstetrics and Gynecology, 2012, 51, 533-538.	0.5	30
371	Genital warts: diagnosis, management, and prevention. NursePrescribing, 2012, 10, 392-394.	0.1	0
372	Use of modelling and simulation techniques to support decision making on the progression of PF-04878691, a TLR7 agonist being developed for hepatitis C. British Journal of Clinical Pharmacology, 2012, 73, 77-92.	1.1	9
373	2012 European guideline for the management of anogenital warts. Journal of the European Academy of Dermatology and Venereology, 2013, 27, e263-70.	1.3	152

#	ARTICLE	IF	CITATIONS
374	TLR Signaling and DNA Repair: Are They Associated?. Journal of Investigative Dermatology, 2013, 133, 296-302.	0.3	36
375	New Treatments for Human Papillomavirus Infection. Actas Dermo-sifiligráficas, 2013, 104, 883-889.	0.2	5
376	Dermatoproctología. EMC - Dermatología, 2013, 47, 1-6.	0.1	0
377	Nuevos tratamientos en la infección por virus del papiloma humano. Actas Dermo-sifiligráficas, 2013, 104, 883-889.	0.2	15
378	Mécanismes d'action de l'imiquimod et implication dans le traitement des affections cutanées virales humaines et animales. Pratique Médicale Et Chirurgicale De L'Animal De Compagnie, 2013, 48, 105-112.	0.1	3
379	HSV-1 exploits the innate immune scavenger receptor MARCO to enhance epithelial adsorption and infection. Nature Communications, 2013, 4, 1963.	5.8	39
380	Current update on the treatment of genital warts. Expert Review of Dermatology, 2013, 8, 321-332.	0.3	4
382	Surgical treatment of giant anal condyloma in HIV patients: unanswered questions. Colorectal Disease, 2013, 15, 908-909.	0.7	1
383	TLRs to cytokines: Mechanistic insights from the imiquimod mouse model of psoriasis. European Journal of Immunology, 2013, 43, 3138-3146.	1.6	226
384	New Alternative Combination Therapy for Recalcitrant Common Warts: The Efficacy of Imiquimod 5% Cream and Duct Tape Combination Therapy. Annals of Dermatology, 2013, 25, 261.	0.3	12
385	Recommended Managements for the Male Human Papillomavirus Infection. The Korean Journal of Urogenital Tract Infection and Inflammation, 2014, 9, 79.	0.1	1
387	Genitoanal Human Papillomavirus Infection and Associated Neoplasias. Current Problems in Dermatology, 2014, 45, 98-122.	0.8	10
388	Ultraviolet radiation-induced non-melanoma skin cancer: Regulation of DNA damage repair and inflammation. Genes and Diseases, 2014, 1, 188-198.	1.5	146
389	Imiquimod for anogenital warts in non-immunocompromised adults. The Cochrane Library, 2014, 2014, CD010389.	1.5	31
390	Sinecatechins (Polyphenon E) ointment for treatment of external genital warts and possible future indications. Expert Opinion on Biological Therapy, 2014, 14, 1033-1043.	1.4	30
391	Verruca vulgaris of tympanic membrane treated with topical immunotherapy. American Journal of Otolaryngology - Head and Neck Medicine and Surgery, 2014, 35, 242-245.	0.6	6
392	Topical 5-fluorouracil for treatment of cervical intraepithelial neoplasia 2: a randomized controlled trial. American Journal of Obstetrics and Gynecology, 2014, 210, 314.e1-314.e8.	0.7	41
393	Genital warts and other HPV infections: Established and novel therapies. Clinics in Dermatology, 2014, 32, 299-306.	0.8	45

#	ARTICLE	IF	CITATIONS
394	Induction of vitiligo after imiquimod treatment of condylomata acuminata. BMC Infectious Diseases, 2014, 14, 329.	1.3	29
395	Imiquimod in the Treatment of Cutaneous Warts: An Evidence-Based Review. American Journal of Clinical Dermatology, 2014, 15, 387-399.	3.3	35
397	Citric acid 50% solution versus tretinoin 0.05% lotion in the treatment of plane warts. Journal of the Egyptian Women's Dermatologic Society, 2015, 12, 113-119.	0.2	1
398	Tratamiento de las verrugas genitales: una actualización. Revista Chilena De Obstetricia Y Ginecologia, 2015, 80, 76-83.	0.1	2
399	HPV Carcinomas in Immunocompromised Patients. Journal of Clinical Medicine, 2015, 4, 260-281.	1.0	97
400	Metastatic Melanoma – A Review of Current and Future Treatment Options. Acta Dermato-Venereologica, 2015, 95, 516-524.	0.6	186
401	Advances in Toll-like receptor biology: Modes of activation by diverse stimuli. Critical Reviews in Biochemistry and Molecular Biology, 2015, 50, 359-379.	2.3	71
402	Sexually Transmitted Infections. Urologic Clinics of North America, 2015, 42, 507-518.	0.8	29
403	A randomized trial of efficacy of beta-sitosterol and its glucoside as adjuvant to cryotherapy in the treatment of anogenital warts. Journal of Dermatological Treatment, 2015, 26, 139-142.	1.1	3
404	Papillomavirus. , 2016, , 625-678.		0
405	Efficacy of Imiquimod Cream Administered Intraperitoneally for Ovarian Metastases in Colorectal Cancer. Gynecology & Obstetrics (Sunnyvale, Calif), 2016, 6, .	0.1	1
407	Treatment of condyloma acuminata in pregnant women with cryotherapy combined with proanthocyanidins: Outcome and safety. Experimental and Therapeutic Medicine, 2016, 11, 2391-2394.	0.8	20
410	TLR-7 activation enhances IL-22-mediated colonization resistance against vancomycin-resistant enterococcus. Science Translational Medicine, 2016, 8, 327ra25.	5.8	77
411	Combined treatment of anogenital HPV infection with cryodestruction, podophyllin 25% and post-ablation immunomodulation with sincatechins 15% ointment – a retrospective analysis. International Journal of STD and AIDS, 2016, 27, 1071-1078.	0.5	15
412	Self-administered interventions for anogenital warts in immunocompetent patients: a systematic review and meta-analysis. Sexually Transmitted Infections, 2017, 93, 155-161.	0.8	29
413	CXCL17 Attenuates Imiquimod-Induced Psoriasis-like Skin Inflammation by Recruiting Myeloid-Derived Suppressor Cells and Regulatory T Cells. Journal of Immunology, 2017, 198, 3897-3908.	0.4	47
414	TLR7 and TLR8, Resiquimod, and 852A. , 2017, , 487-494.		0
415	Sincatechins and imiquimod as proactive sequential therapy of external genital and perianal warts in adults. International Journal of STD and AIDS, 2017, 28, 1433-1443.	0.5	13

#	ARTICLE	IF	CITATIONS
416	9-Phenanthrol enhances the generation of an CD8 + T cell response following transcutaneous immunization with imiquimod in mice. <i>Journal of Dermatological Science</i> , 2017, 87, 260-267.	1.0	5
417	Transcutaneous immunization with a novel imiquimod nanoemulsion induces superior T cell responses and virus protection. <i>Journal of Dermatological Science</i> , 2017, 87, 252-259.	1.0	22
419	Microwave therapy for cutaneous human papilloma virus infection. <i>European Journal of Dermatology</i> , 2017, 27, 511-518.	0.3	19
420	A case of reccuring giant condyloma of vulva in infant without sexual abuse successfully treated with electrocoagulation in Benin. <i>Pan African Medical Journal</i> , 2017, 27, 159.	0.3	5
421	A <i>Solanum incanum</i> extract (SR-T100) regresses vulvar condyloma acuminatum and induces distinct autophagic and apoptotic responses in different types of HPV-infected cells. <i>Translational Medicine Communications</i> , 2017, 2, .	0.5	1
422	Genital warts treatment: Beyond imiquimod. <i>Human Vaccines and Immunotherapeutics</i> , 2018, 14, 1815-1819.	1.4	35
423	Dermatologische Erkrankungen des Anorektums. , 2018, , 393-414.		1
424	Human papillomavirus infection: protocol for a randomised controlled trial of imiquimod cream (5%) versus podophyllotoxin cream (0.15%), in combination with quadrivalent human papillomavirus or control vaccination in the treatment and prevention of recurrence of anogenital warts (HIPvac) Tj ETQq1 1 0.784314rgBT /Overlock 10	1.4	19
425	Structural Analyses of Toll-like Receptor 7 Reveal Detailed RNA Sequence Specificity and Recognition Mechanism of Agonistic Ligands. <i>Cell Reports</i> , 2018, 25, 3371-3381.e5.	2.9	98
426	Trial Watch: Toll-like receptor agonists in cancer immunotherapy. <i>Oncolmmunology</i> , 2018, 7, e1526250.	2.1	172
427	Tollâ€like receptors: Important immune checkpoints in the regression of cervical intraâ€epithelial neoplasia 2. <i>International Journal of Cancer</i> , 2018, 143, 2884-2891.	2.3	17
428	Local Management of Anogenital Warts in Non-immunocompromised Adults: A Systematic Review and Meta-analyses of Randomized Controlled Trials. <i>Dermatology and Therapy</i> , 2019, 9, 761-774.	1.4	5
429	Effectiveness of topical and ablative therapies in treatment of anogenital warts: a systematic review and network meta-analysis. <i>BMJ Open</i> , 2019, 9, e027765.	0.8	17
430	Diode lasers for the treatment of genital warts. <i>European Journal of Dermatology</i> , 2019, 29, 409-416.	0.3	5
431	Position statement for the diagnosis and management of anogenital warts. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2019, 33, 1006-1019.	1.3	45
432	Development of resiquimod-loaded modified PLA-based nanoparticles for cancer immunotherapy: A kinetic study. <i>European Journal of Pharmaceutics and Biopharmaceutics</i> , 2019, 139, 253-261.	2.0	28
433	Topical sinecatechins in the treatment of verrucae planae of the face. <i>Dermatologic Therapy</i> , 2019, 32, e12891.	0.8	1
434	12 Condyloma Acuminatum. , 2019, , .		0

#	ARTICLE	IF	CITATIONS
435	Topically applied treatments for external genital warts in nonimmunocompromised patients: a systematic review and network meta-analysis. <i>British Journal of Dermatology</i> , 2020, 183, 24-36.	1.4	15
436	TLR7 Stimulation With Imiquimod Induces Selective Autophagy and Controls Mycobacterium tuberculosis Growth in Mouse Macrophages. <i>Frontiers in Microbiology</i> , 2020, 11, 1684.	1.5	17
437	2019 IUSTI Europe guideline for the management of anogenital warts. <i>Journal of the European Academy of Dermatology and Venereology</i> , 2020, 34, 1644-1653.	1.3	66
438	Imiquimod does not elicit inflammatory responses in the skin of the naked mole rat (<i>Heterocephalus</i>) Tj ETQq1 1 0.784314 rgBT /Ove	0.6	3
439	Biomaterials for Immunoengineering. , 2020, , 1199-1215.		1
440	Local Management of Anogenital Warts in Non-Immunocompromised Adults: A Network Meta-Analysis of Randomized Controlled Trials. <i>Dermatology and Therapy</i> , 2020, 10, 249-262.	1.4	11
441	Topical and Intralesional Antiviral Agents. , 2021, , 493-503.e4.		1
442	Topical chemotherapy for penile carcinoma in situ: Contemporary outcomes and reported toxicity. <i>Urologic Oncology: Seminars and Original Investigations</i> , 2021, 39, 72.e1-72.e5.	0.8	3
443	Treatment of intra-anal warts with imiquimod 5% cream: A single-center prospective open study. <i>Journal of Dermatology</i> , 2021, 48, 476-480.	0.6	4
444	Viral Venereal Diseases of the Skin. <i>American Journal of Clinical Dermatology</i> , 2021, 22, 523-540.	3.3	3
445	Evolution of Toll-like receptor 7/8 agonist therapeutics and their delivery approaches: From antiviral formulations to vaccine adjuvants. <i>Advanced Drug Delivery Reviews</i> , 2021, 175, 113803.	6.6	76
446	Intra-Anal Imiquimod Cream against Human Papillomavirus Infection in Men Who Have Sex with Men Living with HIV: A Single-Arm, Open-Label Pilot Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 4477.	1.0	0
447	Non-Operative Options for Loco-regional Melanoma. <i>Clinics in Plastic Surgery</i> , 2021, 48, 631-642.	0.7	1
449	Topical Therapy. , 0, , 3965-4016.		4
451	The Epidemiology of Human Papillomavirus Infections. <i>Cancer Prevention, Cancer Causes</i> , 2004, , 143-187.	0.3	6
453	Human Papilloma Virus Infections. , 2009, , 64-73.		1
454	Papillomaviruses. , 2010, , 2035-2049.		3
455	THERAPEUTIC VACCINES FOR CONTROL OF HUMAN PAPILLOMAVIRUS CHRONIC INFECTIONS. , 2000, , 273-293.		2

#	ARTICLE	IF	CITATIONS
457	2. Imiquimod: Mode of Action and Therapeutic Potential. <i>Acta Dermato-Venereologica</i> , 2003, 83, 8-11.	0.6	8
458	In Vitro Immunomodulation of a Whole Blood IFN- γ Release Assay Enhances T Cell Responses in Subjects with Latent Tuberculosis Infection. <i>PLoS ONE</i> , 2012, 7, e48027.	1.1	10
459	Efficacy of Imiquimod-Based Transcutaneous Immunization Using a Nano-Dispersed Emulsion Gel Formulation. <i>PLoS ONE</i> , 2014, 9, e102664.	1.1	37
460	Avanços no tratamento da leishmaniose tegumentar do novo mundo nos últimos dez anos: uma revisão sistemática da literatura. <i>Anais Brasileiros De Dermatologia</i> , 2011, 86, 497-506.	0.5	52
461	Clinical effectiveness and cost-effectiveness of interventions for the treatment of anogenital warts: systematic review and economic evaluation. <i>Health Technology Assessment</i> , 2016, 20, 1-486.	1.3	47
462	Imiquimod versus podophyllotoxin, with and without human papillomavirus vaccine, for anogenital warts: the HIPvac factorial RCT. <i>Health Technology Assessment</i> , 2020, 24, 1-86.	1.3	16
463	Systematic Review of Imiquimod for the Treatment of External Genital Wart. <i>International Journal of Pharmacology</i> , 2006, 3, 1-10.	0.1	8
464	An open, nonrandomized, comparative study of imiquimod 5% cream versus 10% potassium hydroxide solution in the treatment of molluscum contagiosum. <i>Indian Journal of Dermatology, Venereology and Leprology</i> , 2008, 74, 614.	0.2	31
465	Immunotherapy of viral warts: myth and reality. <i>Egyptian Journal of Dermatology and Venerology</i> , 2015, 35, 1.	0.1	15
466	Management of gynecologic patients with precancerous disease. <i>Korean Journal of Obstetrics and Gynecology</i> , 2010, 53, 291.	0.1	3
467	A short, 8-week course of imiquimod 5% cream versus podophyllotoxin in the treatment of anogenital warts: A retrospective comparative cohort study. <i>Indian Journal of Dermatology, Venereology and Leprology</i> , 2021, 87, 666-670.	0.2	2
468	Complications and dosing frequency of 5% imiquimod for genital warts in a young man. <i>Clinical Research in Practice the Journal of Team Hippocrates</i> , 2021, 7, .	0.0	0
469	Immuntherapie bei Genital- und Perianalwarzen-Imiquimod " eine Innovation mit großem Potential. , 2000, , 322-323.		0
470	Miscellaneous Surgical Procedures: Treatments for Condyloma Acuminatum, Sacrococcygeal Pilonidal Disease, and Fecal Impaction; Examination Under Anesthesia; and Minor Revision of Intestinal Stomas. , 2000, , 143-160.		1
471	Imiquimod " Stellenwert bei der genitoanalen HPV-Infektion. , 2000, , 324-327.		0
473	Ulzerationen und tumoröse Läsionen des Penis (Peniskarzinom s. Befund 40). , 2001, , 312-323.		0
474	Genitoanale HPV-Infektionen - Imiquimod. <i>Fortschritte Der Praktischen Dermatologie Und Venerologie</i> , 2001, , 343-347.	0.0	2
476	Update in Dermatology. <i>Annals of Internal Medicine</i> , 2001, 135, 124.	2.0	0

#	ARTICLE	IF	CITATIONS
477	Papillomaviruses. , 2002, , 257-278.		1
478	Sexuell ¼bertragbare Erkrankungen und andere andrologisch bedeutsame Infektionen. , 2002, , 209-224.		0
479	Treatment of Anal Condyloma Acuminatum Using an Antiviral Ointment.. Nihon Daicho Komonbyo Gakkai Zasshi, 2003, 56, 412-416.	0.1	0
480	Skin Infections and Infestations. , 2003, , 991-1004.		0
481	Perianal lokalisierte Krankheitsbilder. , 2003, , 113-230.		0
482	Perianal Skin Diseases. , 2003, , 107-222.		0
483	Prevention of Gynecologic Malignancies. , 2004, , 883-919.		0
484	Haut- und Weichteilinfektionen. , 2004, , 438-468.		1
486	Imiquimod: F¼r alles gut?. Fortschritte Der Praktischen Dermatologie Und Venerologie, 2005, , 539-543.	0.0	0
487	Virale Erkrankungen: Klinik, Diagnostik und Therapie. Fortschritte Der Praktischen Dermatologie Und Venerologie, 2005, , 475-483.	0.0	0
488	Human Papillomavirus and Genital Warts. , 2006, , 21-46.		1
489	Viral treatment and prophylactic vaccination strategies. , 2006, , 55-72.		0
490	Vulvar Therapies. , 2006, , 115-150.		0
494	Cutaneous Viral Diseases. , 2009, , 835-852.		0
496	Topical Therapies of External Ear Disorders. , 2010, , 1950-1962.		3
500	Management of genital warts. Independent Nurse, 2012, 2012, .	0.0	0
501	Human Papillomavirus and Genital Warts. , 2013, , 1-17.		2
502	TLR7 and TLR8, Resiquimod, and 852A. , 2013, , 1-8.		0

#	ARTICLE	IF	CITATIONS
503	Management of Over-Granulation in a Diabetic Foot Ulcer: A Clinical Experience. Indian Journal of Physical Medicine and Rehabilitation, 2013, 24, 19-22.	0.1	0
504	Alkohol und Haut. , 1999, , 423-430.		0
505	Problemzone Genitoanalregion. Fortschritte Der Praktischen Dermatologie Und Venerologie, 1999, , 574-579.	0.0	0
506	Papillomaviruses. , 2015, , 1794-1806.e4.		2
507	Anal Condyloma Acuminata and Anal Dysplasia. , 2016, , 189-209.		0
508	Cutaneous Lesions of HIV-Positive Patients. , 2016, , 257-262.		0
509	Topical Immune Response Modifiers: Adjuvants. , 2017, , 775-790.		0
511	Clinical Management of Anogenital Warts and Intraepithelial Neoplasia. , 2020, , 233-254.		0
515	Topical Immune Response Modifiers: Adjuvants. , 2008, , 527-537.		0
516	Immunotherapy of gynaecological high-risk human papilloma virus infection with human leukocyte ultrafiltrate. Infectious Diseases in Obstetrics and Gynecology, 2000, 8, 120-3.	0.4	1
517	Patient-applied treatment for external genital warts: the time has come. Western Journal of Medicine, 1998, 169, 227-8.	0.3	0
518	Warts (genital). Clinical Evidence, 2007, 2007, .	0.2	0
520	Warts (genital). Clinical Evidence, 2010, 2010, .	0.2	0
521	Genital warts: a comprehensive review. Journal of Clinical and Aesthetic Dermatology, 2012, 5, 25-36.	0.1	52
522	Podophyllotoxin: a novel potential natural anticancer agent. Avicenna Journal of Phytomedicine, 2017, 7, 285-294.	0.1	54
523	Human papillomaviruses. , 0, , 371-381.		1
529	Current and future direction in treatment of HPV-related cervical disease. Journal of Molecular Medicine, 2022, 100, 829-845.	1.7	20
530	Topical and intralesional antiviral agents. , 2013, , 473-480.e3.		1

#	ARTICLE	IF	CITATIONS
531	Viral-Host Dependency Factors as Therapeutic Targets to Overcome Antiviral Drug-Resistance: A Focus on Innate Immune Modulation. <i>Frontiers in Virology</i> , 0, 2, .	0.7	5
532	Photodynamic Therapy Using Intense Pulse Light to Treat an HIV Patient With Perianal Squamous Cell Carcinoma: A Case Report. <i>Cureus</i> , 2022, , .	0.2	0
534	Topically Applied Resiquimod versus Imiquimod as a Potential Adjuvant in Melanoma Treatment. <i>Pharmaceutics</i> , 2022, 14, 2076.	2.0	10